Loading patent…
AssigneesPublic University Corporation Yokohama City University, Public University Corporation Nagoya City University, Pharma Foods International Co., Ltd.
InventorsMamoru SATO, Michiyuki YAMADA, Satoshi KANAZAWA, Masayoshi TOYOURA, Yuji SHOYA, Kenji SAITO, Chihiro YAMAZAKI
Estimating the term…
Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.
1-35. (canceled)
An anti-PAD4 antibody comprising heavy chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
A method for inhibiting the citrullination activity of PAD4, comprising a step of administering to a patient an anti-PAD4 antibody.
A method for detecting PAD4, comprising a step of causing a test sample to contact an anti-PAD4 antibody.
Dependencies are inferred from the claim text.